Literature DB >> 2663859

Globotetraosylceramide is recognized by the pig edema disease toxin.

S DeGrandis1, H Law, J Brunton, C Gyles, C A Lingwood.   

Abstract

The pig edema disease toxin has been shown by a tlc glycolipid binding assay to bind specifically to globotetraosylceramide (Gb4, GalNAc beta 1-3Gal alpha 1-4Gal beta 1-4GlcCer.). Binding was reduced for globotriosylceramide (Gb3, Gal alpha 1-4Gal beta 1-4GlcCer) and more markedly for the Forssman antigen (GalNAc alpha 1-3GalNAc beta 1-3Gal alpha 1-4Gal beta 1-4GlcCer). Paragloboside, blood group A glycolipids, glycolipids terminating in Gal NAc beta 1-4Gal-, and glycolipids in which globoside was present as an internal sequence did not bind the toxin. Isogloboside (GalNAc beta 1-3Gal alpha 1-3Gal beta 1-4GlcCer) was efficiently recognized. This toxin is genetically related to the verotoxin (or Shiga-like) family of toxins for which Gb3 has been shown to be the receptor. The difference in susceptibility of cell lines to the cytotoxicity of the pig edema disease toxin and the Shiga and Shiga-like toxins is consistent with the difference in receptor glycolipid binding.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663859

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

3.  Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation.

Authors:  Dakshina M Jandhyala; Trisha J Rogers; Anne Kane; Adrienne W Paton; James C Paton; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

Review 4.  Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion.

Authors:  C L Sears; J B Kaper
Journal:  Microbiol Rev       Date:  1996-03

Review 5.  Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections.

Authors:  Adrienne W Paton; Renato Morona; James C Paton
Journal:  Bioeng Bugs       Date:  2009-11-17

6.  Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.

Authors:  J E Samuel; L P Perera; S Ward; A D O'Brien; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

7.  Identification of a wide range of motifs inhibitory to shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane.

Authors:  Mihoko Kato; Miho Watanabe-Takahashi; Eiko Shimizu; Kiyotaka Nishikawa
Journal:  Appl Environ Microbiol       Date:  2014-12-01       Impact factor: 4.792

8.  Effectiveness of egg yolk antibody against shiga toxin II variant toxicity in vitro and in vivo.

Authors:  Yufei Feng; Wenxin Liu; Dongfang Shi
Journal:  Curr Microbiol       Date:  2013-05-21       Impact factor: 2.188

9.  The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.

Authors:  S W Lindgren; J E Samuel; C K Schmitt; A D O'Brien
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

10.  In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.

Authors:  Kwang-il Jeong; Susan Chapman-Bonofiglio; Pradeep Singh; Jongo Lee; Saul Tzipori; Abhineet S Sheoran
Journal:  BMC Immunol       Date:  2010-03-24       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.